NantKwest Revenue and Competitors
Estimated Revenue & Valuation
- NantKwest's estimated annual revenue is currently $3.9M per year.
- NantKwest's estimated revenue per employee is $77,500
- NantKwest's total funding is $103.5M.
Employee Data
- NantKwest has 50 Employees.
- NantKwest grew their employee count by -17% last year.
NantKwest's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | vp Research & Development | Reveal Email/Phone |
3 | SVP, Medical Affairs for Pediatric, Adolescent and Young Adult Oncology | Reveal Email/Phone |
4 | Head Operations Project Management | Reveal Email/Phone |
5 | General Counsel | Reveal Email/Phone |
6 | Director Operations | Reveal Email/Phone |
7 | Senior Director, Infectious Diseases | Reveal Email/Phone |
8 | Director Supply Chain Management | Reveal Email/Phone |
9 | Director, Global Quality Assurance | Reveal Email/Phone |
10 | President & Chief Administrative Officer | Reveal Email/Phone |
NantKwest Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is NantKwest?
NantKwest (NASDAQ: NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the bodyᅢᄁ¬ツᆲ¬トᄁs first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our ᅢᄁ¬ツᆲᅤモoff-the-shelfᅢᄁ¬ツᆲᅡン activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an ᅢᄁ¬ツᆲᅤモoff-the-shelfᅢᄁ¬ツᆲᅡン living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.
keywords:N/A$103.5M
Total Funding
50
Number of Employees
$3.9M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NantKwest News
The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest Inc.,...
Takeda Pharmaceutical, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, NKT Therapeutics. This comprehensive K Cells Market report helps in...
... Mustang Bio Inc, NantKwest Inc., Neuralstem Inc, NexImmune Inc., Nohla Therapeutics Inc, ReNeuron Group plc, Richter-Helm BioLogics GmbH & Co.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.2M | 50 | 6% | N/A |
#2 | $5.8M | 50 | -6% | N/A |
#3 | $6.9M | 51 | 6% | N/A |
#4 | $12.9M | 53 | 2% | N/A |
#5 | N/A | 53 | 23% | N/A |